NasdaqGM - Nasdaq Real Time Price USD

Gain Therapeutics, Inc. (GANX)

Compare
1.7800 0.0000 (0.00%)
As of 12:13 PM EDT. Market Open.
Loading Chart for GANX
DELL
  • Previous Close 1.7800
  • Open 1.8500
  • Bid 1.7400 x 400
  • Ask 1.8000 x 100
  • Day's Range 1.5380 - 1.8500
  • 52 Week Range 0.8900 - 5.3300
  • Volume 224,439
  • Avg. Volume 350,131
  • Market Cap (intraday) 45.453M
  • Beta (5Y Monthly) 0.35
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3100
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 7.40

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.

www.gaintherapeutics.com

29

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GANX

View More

Performance Overview: GANX

Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GANX
45.48%
S&P 500
20.29%

1-Year Return

GANX
44.55%
S&P 500
32.28%

3-Year Return

GANX
76.04%
S&P 500
28.78%

5-Year Return

GANX
84.52%
S&P 500
46.63%

Compare To: GANX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GANX

View More

Valuation Measures

Annual
As of 9/25/2024
  • Market Cap

    45.45M

  • Enterprise Value

    29.32M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.86

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -72.96%

  • Return on Equity (ttm)

    -188.83%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -21.6M

  • Diluted EPS (ttm)

    -1.3100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.94M

  • Total Debt/Equity (mrq)

    6.85%

  • Levered Free Cash Flow (ttm)

    -10.06M

Research Analysis: GANX

View More

Company Insights: GANX

Research Reports: GANX

View More

People Also Watch